Condition
Open-angle Glaucoma (OAG)
Total Trials
6
Recruiting
2
Active
2
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 6 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
33%
1 of 3 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (1)
P 2 (4)
Trial Status
Completed3
Recruiting2
Enrolling By Invitation1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT07408154Not ApplicableRecruitingPrimary
Direct vs Standard SLT for Glaucoma: A Noninferiority Trial
NCT07480343Enrolling By InvitationPrimary
5-Year Postoperative Outcomes of Patients Who Completed the CREST Study
NCT07354477Phase 2Recruiting
Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation
NCT06249152Phase 2CompletedPrimary
Qlaris Study of QLS-111 in Combination With a PGA for OAG and/or OHT Patients
NCT01318252Phase 2CompletedPrimary
AL-54478 Proof of Concept Study
NCT01114893Phase 2CompletedPrimary
Travoprost Five Day Posology Study
Showing all 6 trials